Effect of Nano-drugs on Tumor Immune Microenvironment
GAO Chun-xiao1, WEI Xun-dong1, HUANG Wei2, YUAN Wei3, MA Jie1*
Author information+
1. Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China; 2. School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China; 3. National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
In recent years, benefiting from advances in tumor immunity research, cancer treatment and diagnostic techniques have advanced by leaps and bounds. The combination of nano-medicine and tumor immunotherapy gestate huge opportunities in anti-tumor therapy. However, the clinical application of nano-medicine is also facing the challenge of biological safety, and the mechanism of synergy between nano-medicine and body immunity has yet to be elucidated. This article summarizes the characteristics and mechanism of nanomedicine's effect on tumor immune microenvironment, focusing on how nano-medicine can activate and stimulate innate immunity and adaptive immunity and then regulate the function of tumor immune microenvironment.
[1] THOMAS P D, KAHN M. Kat3 coactivators in somatic stem cells and cancer stem cells: biological roles, evolution, and pharmacologic manipulation[J]. Cell Biol Toxicol, 2016, 32(1):61-81. [2] WHERRY E J. T cell exhaustion[J]. Nat Immunol, 2011, 12(6):492-499. [3] FRIDMAN W H, PAGÈS, FRANCK, SAUTÈS-FRIDMAN, CATHERINE, et al. The immune contexture in human tumours: impact on clinical outcome[J]. Nat Rev Cancer, 2012, 12(4):298-306. [4] JOHN, REISER, ARNOB, et al. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response [J]. J Immunol Res, 2016,2016:8941260. doi: 10.1155/2016/8941260. [5] FEUERER M, ROCHA M, BAI L, et al. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients[J]. Int J Cancer, 2001, 92(1):96-105. [6] FRANCK PAGèS, BERGER A, CAMUS M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer[J]. New England J Med, 2006, 353(25):2654-2666. [7] GANESAN A P, CLARKE J, WOOD O, et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer[J]. Nat Immunol, 2017,18(8): 940-950. [8] WEBB J R, MILNE K, NELSON B H. PD-1 and CD103 are widely coexpressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer[J]. Cancer Immunol Res, 2015, 3(8):926-935. [9] QIAN B Z, LI J F, ZHANG H, et al. CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis[J]. Nature, 2012, 475(7355):222-225. [10] HELENA, JANOLS, CAROLINE, et al. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases[J]. J Leukoc Biol, 2014, 96(5): 685-693. [11] YU J, DU W, YAN F, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer [J]. J Immunol, 2013, 190(7): 3783-3797. [12] NISHIKAWA H, SAKAGUCHI S. Regulatory T cells in cancer immunotherapy[J]. Curr Opin Immunol, 2014, 55(10): 2183-2189. [13] LI W, YANG J, LUO L, et al. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death[J]. Nat Commun, 2019, 10(1):3349. [14] WU C, GUAN X, XU J, et al. Highly efficient cascading synergy of cancer photo-immunotherapy enabled by engineered graphene quantum dots/photosensitizer/CpG oligonucleotides hybrid nanotheranostics[J]. Biomaterials, 2019, 205:106-119. [15] BARILLET S, FATTAL E, MURA S, et al. Immunotoxicity of poly (lactic-co-glycolic acid) nanoparticles: influence of surface properties on dendritic cell activation[J]. Nanotoxicology, 2019, 13(5):606-622. [16] STEENBLOCK E R, FAHMY T M. A comprehensive platform for Ex Vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells[J]. Mol Ther, 2008, 16(4):765-772. [17] FREEMAN G J, SHARPE A H, KEIR M E, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26(1):677-704. [18] TOPALIAN S L, HODI F S, BRAHMER J R, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. New England J Med, 2012, 366(26):2443-2454. [19] UYTTENHOVE C, PILOTTE L, THéATE, IVAN, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase[J]. Nat Med, 2003, 9(10):1269-1274. [20] PRASMICKAITE L, TENSTAD E M, PETTERSEN S, et al. Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4[J]. Mol Oncol, 2018, 12(9): 1540-1558. [21] DE GROOT A E, PIENTA K J. Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages[J]. Oncotarget, 2018, 9(29): 20908-20927. [22] GUERRIERO, JENNIFER L. Macrophages: the road less traveled, changing anticancer therapy[J]. Trends Mol Med, 2018, 24(5): 472-489. [23] TAN Y S, SANSANAPHONGPRICHA K, XIE Y, et al. Mitigating SOX2-potentiated immune escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing nanosatellite vaccine[J]. Clin Cancer Res, 2018, 24(17): 4242-4255. [24] WANG J C, SUN X, MA Q, et al. Metformin's antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization[J]. J Cell Mol Med, 2018, 22(8): 3825-3836. [25] TZENG H T, SU C C, CHANG C P, et al. Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages towards tumor-suppressing phenotype[J]. Int J Cancer, 2018, 143(7): 1753-1763. [26] MANTOVANI A, ALLAVENA P. The interaction of anticancer therapies with tumor-associated macrophages[J]. J Exp Med, 2015, 212(4):435-445. [27] RONALD S WEINSTEIN, SHRIRAM M JAKATE, JOSE M DOMINGUEZ, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis[J]. Cancer Res, 1991, 51(10):2720-2726. [28] HABER M, HENDERSON M J, NORRIS M D, et al. ABC transporters in cancer: more than just drug efflux pumps[J]. Nat Rev Cancer, 2010, 10(2):147-156. [29] WANG L, LI W, LU J, et al. Supramolecular nano-aggregates based on bis(pyrene) derivatives for lysosome-targeted cell imaging[J]. J Phy Chem C, 2013, 117(50):26811-26820. [30] ZITZMANN S, EHEMANN V, SCHWAB M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo[J]. Cancer Res, 2002, 62(18):5139-5143. [31] KALAFATOVIC D, NOBIS M, SON J, et al. MMP-9 triggered self-assembly of doxorubicin nanofiber depots halts tumor growth[J]. Biomaterials, 2016, 98:192-202. [32] TSOI K M, MACPARLAND S A, MA X Z, et al. Mechanism of hard-nanomaterial clearance by the liver[J]. Nat Mater, 2016, 15(11):1212-1221. [33] WONG Y Q W, YEO C H F, ANG W H, Induction of immunogenic cell death by chemotherapeutic platinum complexes[J]. Angew Chem Int Ed Engl, 2015, 127(22):6583-6587. [34] NELLY PANTé, KANN M. Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm[J]. Mol Biol Cell, 2002, 13(2):425-434. [35] TANG X, MO C, WANG Y, et al. Anti-tumour strategies aiming to target tumour-associated macrophages[J]. Immunology, 2013, 138(2):93-104. [36] JOÃO, CONDE, CHENCHEN, et al. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumor-associated macrophages and cancer cells[J]. Adv Funct Mater, 2015, 25(27): 4183-4194. [37] SYLVESTRE M, CRANE C A, PUN S H. Progress on modulating tumor-associated macrophages with biomaterials[J]. Adv Mater, 2020, 32(13): e1902007. doi: 10.1002/adma.201902007. [38] LEDO A M, SASSO M S, BRONTE V, et al. Co-delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid-derived suppressor cells[J]. J Controlled Release, 2019, 295:60-73. [39] BURKERT S C, SHURIN G V, WHITE D L, et al. Targeting myeloid regulators by paclitaxel-loaded enzymatically degradable nanocups[J]. Nanoscale, 2018, 10(37): 17990-18000. [40] LÓPEZ-SOTO, ALEJANDRO, GONZALEZ S, SMYTH M J, et al. Control of metastasis by NK Cells[J]. Cancer Cell, 2017, 32(2):135-154. [41] HANS K, LAURENT B, FRANCES T. Natural killer cells for immunotherapy-advantages of the NK-92 cell line over blood NK cells[J]. Front Immunol, 2016, 7(91): 1-7. [42] CHAN A C, CARTER P J. Therapeutic antibodies for autoimmunity and inflammation[J]. Nat Rev Immunol, 2010, 10(5):301-316. [43] VIVIER E, TOMASELLO, BARATIN M, et al. Functions of natural killer cells[J]. Nat Immunol, 2008, 9(5):503-510. [44] ZHANG C, GUAN Y, SUN Y, et al. Tumor heterogeneity and circulating tumor cells[J]. Cancer Lett, 2016, 374(2):216-223. [45] JI T, LANG J, NING B, et al. Enhanced natural killer cell immunotherapy by rationally assembling Fc fragments of antibodies onto tumor membranes[J]. Adv Mater, 2019, 31(6): e1804395. doi: 10.1002/adma.201804395. [46] QIN D, STEFAN W, DING D, et al. Quantifying the ligand-coated nanoparticle delivery to cancer cells in solid tumors[J]. ACS Nano, 2018, 12(8): 8423-8435. [47] SANMAMED M F, CHESTER C, MELERO I, et al. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies[J]. Ann Oncol, 2016, 27(7): 1190-1198.